(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología terapia génica > DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista >

Immunotherapy and immunoescape in colorectal cancer
Autor(es) : Mazzolini, G. (Guillermo)
Murillo, O. (Oihana)
Atorrasagasti, C. (Catalina)
Dubrot, J. (Juan)
Tirapu, I. (Íñigo)
Rizzo, M. (Miguel)
Arina, A. (Ainhoa)
Alfaro, C. (Carlos)
Azpilicueta, A. (Arantza)
Berasain, C. (Carmen)
Perez-Gracia, J.L. (José Luis)
Gonzalez, A. (Álvaro)
Melero, I. (Ignacio)
Palabras clave : Colorectal carcinoma
Immunotherapy
Gene therapy
Interleukin-12
Dendritic cells
CD137
Indoleamine 2, 3 dioxygenase
Fecha incorporación: 2007
Editorial : Baishideng Publishing
Versión del editor: http://www.wjgnet.com/1007-9327/full/v13/i44/5822.htm
ISSN: 2219-2840
Cita: Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, et al. Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 2007 Nov 28;13(44):5822-5831.
Resumen
Immunotherapy encompasses a variety of interventions and techniques with the common goal of eliciting tumor cell destructive immune responses. Colorectal carcinoma often presents as metastatic disease that impedes curative surgery. Novel strategies such as active immunization with dendritic cells (DCs), gene transfer of cytokines into tumor cells or administration of immunostimulatory monoclonal antibodies (such as anti-CD137 or anti-CTLA-4) have been assessed in preclinical studies and are at an early clinical development stage. Importantly, there is accumulating evidence that chemotherapy and immunotherapy can be combined in the treatment of some cases with colorectal cancer, with synergistic potentiation as a result of antigens cross-presented by dendritic cells and/or elimination of competitor or suppressive T lymphocyte populations (regulatory T-cells). However, genetic and epigenetic unstable carcinoma cells frequently evolve mechanisms of immunoevasion that are the result of either loss of antigen presentation, or an active expression of immunosuppressive substances. Some of these actively immunosuppressive mechanisms are inducible by cytokines that signify the arrival of an effector immune response. For example, induction of 2, 3 indoleamine dioxygenase (IDO) by IFNgamma in colorectal carcinoma cells. Combinational and balanced strategies fostering antigen presentation, T-cell costimulation and interference with immune regulatory mechanisms will probably take the stage in translational research in the treatment of colorectal carcinoma.
Enlace permanente: http://hdl.handle.net/10171/21731
Aparece en las colecciones: DA - CIMA - Terapia génica y Hepatología - Oncobiología - Artículos de revista
DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista

Ficheros en este registro:

No hay ficheros asociados a este ítem.

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.